πŸ‡ΊπŸ‡Έ FDA
Patent

US 9273315

Modulation of huntingtin expression

granted A61PA61P1/00A61P15/00

Quick answer

US patent 9273315 (Modulation of huntingtin expression) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P1/00, A61P15/00, A61P19/10, A61P21/02